Platelet activation risk index as a prognostic thrombosis indicator

K. E. Zlobina¹ & G. Th. Guria¹,²

Platelet activation in blood flow under high, overcritical shear rates is initiated by Von Willebrand factor. Despite the large amount of experimental data that have been obtained, the value of the critical shear rate, above which von Willebrand factor starts to activate platelets, is still controversial. Here, we recommend a theoretical approach to elucidate how the critical blood shear rate is dependent on von Willebrand factor size. We derived a diagram of platelet activation according to the shear rate and von Willebrand factor multimer size. We succeeded in deriving an explicit formula for the dependence of the critical shear rate on von Willebrand factor molecule size. The platelet activation risk index was introduced. This index is dependent on the flow conditions, number of monomers in von Willebrand factor, and platelet sensitivity. Probable medical applications of the platelet activation risk index as a universal prognostic index are discussed.

In many cases, intravascular blood coagulation, followed by myocardial infarctions and strokes, is known to be the result of rapid increase in arterial pressure and relevant hemodynamic characteristics such as blood velocity and flow shear rate¹,². However, modern clinical tests are limited to predict thrombotic or bleeding risk because they measure clotting behavior under static (no flow) conditions³. Only first steps are made towards development of diagnostic methods and devices for measuring effects of hemodynamic forces that contribute to platelet function and thrombus formation⁴,⁵.

Von Willebrand factor (VWF) plays a central role in transmitting the dynamic effect of blood flow shear stress to intracellular platelet activation pathways⁶–¹³. VWF has a multimer structure, consisting of 2–80 monomers per multimer in the blood of healthy donors¹⁴,¹⁵. Each monomer contains an A1 domain that is capable of binding to the platelet receptor GP-Ib, thereby initiating platelet activation. VWF is present in blood in the globular form. Following an increase in shear rate, it unfolds into an elongated form, which has an increased binding ability¹⁶,¹⁷ (Fig. 1).

![Diagram of platelet activation](image)

**Figure 1.** Partially unfolded VWF molecule globule in shear flow, r denotes the radius of the globular part, x is a length of the unfolded “tail”. Diameter of a single chain of multimer is denoted as d. Blood shear rate is denoted as \(\dot{\gamma}\). \(F_f\) is the folding force and \(F_{un}\) is the unfolding force.

¹National Research Center for Hematology, 125167, Novy Zykovsky pr. 4, Moscow, Russia. ²Moscow Institute of Physics and Technology, 141700, Institututski per. 9, Dolgoprudny, Russia. Correspondence and requests for materials should be addressed to G.Th.G. (email: guria@blood.ru)
It is known that platelet activation by VWF in a shear flow occurs only at high, overcritical shear rates. However, until recently, the value of the critical shear rate has been controversial, despite the presence of numerous experimental data. It is well established that the value of the critical shear rate $\dot{\gamma}_{cr}$ is between 1000 sec$^{-1}$ and 10000 sec$^{-1}$.

The presence of large VWF multimers in blood causes thrombotic disorders, while the decreased size of VWF multimers is known to be a factor in bleeding disorders. The actual dependence of the critical shear rate value $\dot{\gamma}_{cr}$ on VWF molecule size has not yet been discussed.

### Von Willebrand factor unfolding

A VWF multimer grafted onto a platelet surface in shear flow (Fig. 1) is exposed to at least two forces. The first force, $F_{un}$, is induced by the ongoing blood flow and unwinds the multimer from the globular to the stretched form. The second force, $F_{f}$, is derived from the “effective surface tension,” which tends to wind the multimer into the most compact globular form. Both of these forces are dependent on the multimer size and its conformation.

$$F_f = \sigma \pi d \left[ 1 - \left( \frac{2}{3} \right)^{1/3} \left( L - x \right)^{1/2} \right]$$

$$F_{un} = k \gamma \eta \cdot \pi \cdot d^{4/3} (L - x)^{2/3} \left( \frac{3}{16} \right)^{2/3}$$

where $\sigma$ corresponds to the effective “surface tension”, $d$ refers to the diameter of VWF monomeric subunits, $L$ denotes the total length of the VWF molecule, $x$ denotes the length of the “tail” (the unwound part of the molecule), $\dot{\gamma}$ is shear rate, $\eta$ reflects the value of blood viscosity, $k$ is a dimensionless proportionality coefficient.

A detailed mathematical model of VWF multimer folding-unfolding is presented in the Supplementary information. An analysis of the equilibrium conditions between the folding and unfolding forces revealed three states of VWF grafting on platelets:

- fully folded globular structure;
- partially folded globule with an unfolded “tail”;
- fully unfolded linear structure.

The existence and stability of each of these states are dependent on the VWF multimer size ($n$, monomers per multimer) and shear rate ($\dot{\gamma}$). The parametric plane is presented in Fig. 2.

The condition of the fully folded “globule” state is described by the inequality:
The curve $\gamma_{\text{uni}}(n)$ reaches maximum at $n = n_c = 9/4$. The model is hardly applicable to very short multimers. Further we discuss only the case $n > n_c$.

The curve $\gamma_{\text{uni}}(n)$ monotonically decreases, and the transition from a globule to a partially folded globule with a tail occurs at lower shear rates for larger multimers.

At any fixed value of $n$, a gradual increase in $\gamma_{\text{uni}}$ is followed by several conformational changes in the VWF structure. This is demonstrated in the bifurcation diagram presented in Fig. 3, where $u$ is the relative length of the unfolded VWF tail.

At low shear rates ($\gamma < \gamma_{\text{cr}}$), a VWF multimer is a fully folded globule. If the shear rate increases above $\gamma_{\text{cr}}$, the multimer begins to unfold, becoming a globule with a tail. Further increases in the shear rate above $\gamma_{\text{cr}}$, results in the unwinding of all VWF multimers regardless of their size.

**Platelet activation**

In this study, we assumed that only an unfolded VWF multimer exposing a sufficient amount of A1 domains can activate platelets via simultaneous binding to a group of GP-Ib receptors in an "accord" manner. In other words, we assumed the existence of "minimal platelet activation accord" ($n_A$), i.e., a minimal amount of A1 domains on the unfolded part of VWF, which is sufficient for platelet activation.

In Fig. 4, a platelet activation diagram is presented. The area "U" corresponds to short VWF multimers containing less than the critical number of monomers per multimer, $n < n_A$. VWF is unable to activate platelets.

Domains "S" and "A" correspond to larger VWF multimers, $n > n_A$. In domain "A," the unfolded part of the VWF multimer (i.e., the "tail" in the case of a "globule-with-tail" or the full multimer in the case of a fully unfolded multimer) contains more than $n_A$ monomers. In domain "S," the number of monomers in the unfolded part of VWF is less than $n_A$. In other words, domain "A" corresponds to the conditions required for platelet activation, while "S" domain corresponds to "subcritical" platelet activation and "U" corresponds to non-activation conditions.

The mathematical expression for the value of the critical shear rate $\dot{\gamma}_{\text{cr}}$ sufficient for platelet activation has the form:

$$\dot{\gamma}_{\text{cr}} = \left\{ \begin{array}{ll}
3 \cdot \left( \frac{3}{2} \right)^{4/3} \cdot \gamma_c \cdot \frac{n_A^{1/3} - (2/3)^{1/3}}{n - n_A} & n_A < n < n_A + n_c \\
\gamma_c & n > n_A + n_c
\end{array} \right. \quad (3)$$

(see the Supplementary information).
The necessary and sufficient condition for platelet activation, \( \gamma > \gamma_c \), is equivalent to \( \gamma / \gamma_c > 1 \) for a small interval of VWF multimer sizes, \( 0 < n - n_A < n_c \), and to:

\[
\frac{1}{3} \left( \frac{2}{3} \right)^{\frac{4}{3}} \cdot \frac{\gamma}{\gamma_c} \cdot \frac{n - n_A}{(n - n_A)^{1/3} - (2/3)^{1/3}} > 1
\]

for \( n - n_A > n_c \). We denote the left part of this expression as the "platelet activation risk index" (PARI).

Discussion

To the best of our knowledge, the hypothesis that effective surface tension plays an important role in VWF folding-unfolding dynamics has not yet been analyzed. However, in polymer physics, a similar approach for the determination of the degree of polymer unwinding was developed at the end of the 20th century\(^\text{28,29}\).

By applying the approach developed by De Gennes\(^\text{28}\) and his colleagues\(^\text{29}\) to the VWF dynamics under shear stress conditions on the surface of platelets, we obtained for the first time the exact expression (4) for the dependence of the critical shear rate of platelet activation on VWF multimer size.

An essential assumption introduced in the present work concerns the concept of minimal platelet activation accord. This concept involves the clustering of GPIb receptors on the platelet surface in shear flow, which should enhance platelet interaction with VWF\(^\text{30}\). In this study, we propose that the clustering and cooperative action of platelet GPIb receptors occurred due to their binding to a sufficient amount of A1 domains on the VWF multimer.

Many researchers have observed that long VWF multimers activate platelets more easily while shorter molecules demonstrate a decreased ability to activate platelets or even a lack of ability\(^\text{18,22,23}\). Recently, it was shown that VWF multimers of less than 5500 kDa (22 monomeric units) cannot induce platelet activation\(^\text{23}\). Under the experimental conditions described, \( n_A = 22 \). It is known that the ability of platelets to be activated by VWF varies among different platelet subpopulations\(^\text{31}\). The dependence of \( n_A \) on various pharmaceuticals is of great interest.

VWF multimers are dispersed by size in blood. There is a wide range of hydrodynamic conditions in the blood circulation\(^\text{32}\). Thus, when trying to apply our results to real situations, instead of a specific representation point on the diagrams (Figs 2 and 4), corresponding representation clouds should be considered. The fraction of the representation cloud located in domain "A" on the platelet activation diagram (Fig. 4) should qualitatively reflect the integral intensity of platelet activation.

To easily quantify platelet activation, we introduced the PARI. If PARI < 1, platelets are not activated. If PARI > 1, platelets are activated by VWF. The PARI is dependent on VWF size (n), shear rate (\( \dot{\gamma} \)), and platelet sensitivity (\( n_A \)). The value of \( \dot{\gamma} \) may be calculated mathematically\(^\text{33}\) or directly determined (by MRI or ultrasonic data). The procedure used to determine the VWF size distribution is also known\(^\text{14}\).

There are several methods of regulating the value of PARI, including varying the arterial pressure and vessel geometry or controlling the distribution of VWF size, \( n \).

VWF size is regulated by ADAMTS13, which cuts VWF into shorter multimer fragments\(^\text{33}\). An enhanced shortening of VWF multimers by ADAMTS13 is known as von Willebrand disease 2A\(^\text{25,26}\) (decreased platelet...
activation), and it corresponds to the shifting of representative points to the left in the platelet activation diagram (Fig. 4) and to a decreasing PARI.

The ADAMTS13-related increase in VWF length is known as thrombotic thrombocytopenic purpura and corresponds to a shifting of the representation cloud to the right in the platelet activation diagram (Fig. 4), resulting in easier platelet activation and a tendency toward thrombosis. Additionally, the value of the PARI is increased.

In this study, we found that the value of the critical shear rate of platelet activation is dependent on VWF multimer size. An integrative PARI was introduced. Correction of the PARI may be accomplished by the regulation of system hemodynamics, by a pharmacological change in platelet sensitivity, or by the regulation of VWF by size. The PARI may be used as a universal prognostic index.

References
1. Bonow, R., Mann, D., Zipes, D., Libby, P. (ed.) *Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine*, 9th edition (Philadelphia: WB Saunders Company, 2011).
2. Lowen, B. *The Lost Art of Healing*. 1 Reprint edition (Ballantine Books, 1999).
3. Tynngard, N., Lindahl, T. L. & Ramstrom, S. *Assays of different aspects of haemostasis—what do they measure?* *Thromb. J.* 13, 8 (2015).
4. Jain, A. et al. *A shear gradient-activated microfluidic device for automated monitoring of whole blood haemostasis and platelet function*. *Nat. Commun.* 7, 10176 (2016).
5. Ciorba, M. E., Yu, X., Nesbitt, W. S., Mitchell, A. & Tovar–Lopez, F. J. *Nonlinear dynamic modelling of platelet aggregation via microfluidic devices*. *IEEE Trans Biomed Eng.* 62, 7178–27 (2015).
6. Nesbitt, W. S. et al. *A shear gradient-dependent platelet aggregation mechanism drives thrombus formation*. *Nat Med* 15(6), 665–673 (2009).
7. Kroll, M. H., Hellums, J. D., McIntire, L. V., Schaefer, A. I. & Moake, J. L. *Platelets and shear stress*. *Blood* 88, 1525–1541 (1996).
8. Goto, S., Ikeda, Y., Saldivar, E. & Ruggeri, Z. M. *Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions*. *J Clin Invest.* 101, 479–86 (1998).
9. Ruggeri, Z. M., Orje, J. N., Habermann, R., Federici, A. B. & Reining, A. J. *Activation-independent platelet adhesion and aggregation under elevated shear stress*. *Blood* 108, 1903–1910 (2006).
10. Reining, A. J. *Function of von Willebrand factor in haemostasis and thrombosis*. *Haemophilia* 14(Suppl. 5), 11–26 (2008).
11. Ruggieri, Z. M. *Platelet adhesion under flow*. *Microcirculation* 16, 58–83 (2009).
12. Qin, Y., Ciciliano, J., Myers, D. R., Tran, R. & Lam, W. A. *Platelets and physics: Flow platelets “feel” and respond to their mechanical microenvironment*. *Blood Rev.* 29, 377–386 (2015).
13. Springer, T. A. von Willebrand Factor, Jedi Knight of the Bloodstream. *Blood Journal* 124, 1412–1425 (2014).
14. Di Stasio, E. & De Cristofaro, R. *The effect of shear stress on protein conformation: Physical forces operating on biochemical systems: The case of von Willebrand factor*. *Biophys Chem.* 153, 1–8 (2010).
15. Broekkert, M., Rosa, J.-P. & Lenting, P. J. *Of von Willebrand factor and platelets*. *Blood* 88, 2939–2950 (1996).
16. Siedlecki, C. A. et al. *Shear-dependent changes in the three-dimensional structure of human von Willebrand factor*. *Blood* 88, 2008, 479–86 (1998).
17. Vergauwe, R. M. A. et al. *Shear-Induced Conformational Changes of von Willebrand Factor in a Water–Glycerol Mixture Observed with Single Molecule Microscopy*. *J. Phys. Chem. B* 118, 5660–5669 (2014).
18. Moake, J. L., Turner, N. A., Stathopoulos, N. A., Nolasco, L. H. & Hellums, J. D. *Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation*. *J Clin Invest.* 78, 1456–1461 (1986).
19. Schneider, S. W. et al. *Shear-induced unfolding triggers adhesion of von Willebrand factor fibers*. *PNAS* 104, 7999–7903 (2007).
20. Shankaran, H., Alexandridis, P. & Neelamegham, S. *Aspects of hydrodynamic shear regulating shear-induced platelet activation and self-association of von Willebrand factor in suspension*. *Blood* 101, 2637–2645 (2003).
21. Themistou, E. et al. *Application of fluorescence spectroscopy to quantify shear-induced protein conformation change*. *Biophysical Journal* 97, 2567–2576 (2009).
22. Turner, N. A. & Moake, J. *Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis*. *PLoS One* 8, e59572 (2013).
23. Stockschaider, M., Schneephenr, R. & Budde, U. *Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis*. *Blood Coagul Fibrinolysis* 25, 206–214 (2016).
24. Levy, G. G. et al. *Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura*. *Nature* 413, 488–494 (2001).
25. Sadler, J. E. et al. *Working Party on von Willebrand Disease Classification*. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. *J Thromb Haemost.* 4, 2103–2114 (2006).
26. Gadisseur, A. et al. *Laboratory diagnosis and molecular classification of von Willebrand disease*. *Acta Haematol.* 121, 71–84 (2009).
27. Kim, J., Zhang, C.-Z., Zhang, X. & Springer, T. A. *A mechanically stabilized receptor–ligand flex-bond important in the vasculature*. *Nature* 466, 992–997 (2010).
28. De Gennes, P.-G. *Kinetics of collapse for a flexible coil*. *J. Physique Lett.* 46, 639–642 (1985).
29. Buguin, A. & Brochard-Wyart, F. *Unwinding of Globular Polymers under Strong Flows*. *Macromolecules* 29, 4937–4943 (1996).
30. Gitz, E. et al. *Platelet interaction with von Willebrand factor is enhanced by shear-induced clustering of glycoprotein Ib α*. *Haematologica* 98(11), 1810–1818 (2013).
31. Michelson, A. D. *Platelets*. 3rd ed. (Academic Press, 2013).
32. Caro, C. G., Pealley, T. J., Schroter, R. C. & Seed, W. A. *The mechanics of the circulation* (Oxford University Press, 1978).
33. Rijkshenkloko, O. S., Dudchenko, O. A., Zlobina, K. E. & Guria, G. T. *Mathematical Modeling of Intravascular Coagulation under Wall Shear Stress*. *PLoS One* 10, e0134028, doi: 10.1371/journal.pone.0134028 (2015).
34. Pruthi, P. K. et al. *Plasma von Willebrand factor multimer quantitative analysis by in-gel immunostaining and infrared fluorescent imaging*. *Thromb. Res.* 126, 543–549 (2010).
35. Zheng, X. L. *ADAMTS13 and von Willebrand Factor in Thrombotic Thrombocytopenic Purpura*. *Ann. Rev. Med.* 66, 211–25 (2015).

Acknowledgements
This work was supported by the Russian Scientific Foundation (grant #14-14-00990).

Author Contributions
K.E.Z. and G.Th.G. wrote the main manuscript text and prepared Figures 1–4. All authors reviewed the manuscript.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Zlobina, K. E. and Guria, G. Th. Platelet activation risk index as a prognostic thrombosis indicator. Sci. Rep. 6, 30508; doi: 10.1038/srep30508 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016